Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

Acute and chronic impact of cardiovascular events on health state utilities

(2015) Louis S Matza et al.   BMC HEALTH SERVICES RESEARCH

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

(2015) David Preiss et al.   EUROPEAN HEART JOURNAL

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease

(2015) Ankur Pandya et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

(2014) Jeffrey L. Anderson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Contributions Of Prevention And Treatment To The Decline In Cardiovascular Mortality: Lessons From A Forty-Year Debate

(2013) David S. Jones et al.   HEALTH AFFAIRS

Long-term Clinical Outcomes of Statin Use for Chronic Heart Failure: A Meta-analysis of 15 Prospective Studies

(2013) Jian-Qiang Wang et al.   Heart Lung and Circulation

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication

(2012) Marianne Benn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Forecasting the Future of Cardiovascular Disease in the United States

(2011) Paul A. Heidenreich et al.   CIRCULATION

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure

(2009) Michael J. Lipinski et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia

(2009) L. Nherera et al.   CURRENT MEDICAL RESEARCH AND OPINION

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia

(2009) R Minhas et al.   HEART

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION